Enfortumab Padcev®
The SHIKARI® Enfortumab portfolio combines quantitative free-drug measurement with qualitative anti-enfortumab antibody screening for method-controlled research.
Why Enfortumab is relevant to biological-drug monitoring research
Enfortumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Enfortumab vedotin is a Nectin-4-directed antibody–drug conjugate that delivers the microtubule-disrupting payload monomethyl auristatin E to Nectin-4-expressing cells. Source ↗
Approved Indications
EMA-authorised use is in locally advanced or metastatic urothelial carcinoma in defined settings, including combination treatment with pembrolizumab and later-line monotherapy according to the approved label. EMA source ↗
ADC Exposure After Cycle 1
FDA pharmacokinetic data for the 1.25 mg/kg schedule report antibody–drug-conjugate exposure after the first treatment cycle:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two verified Enfortumab research assays
Ligand-binding ELISA for quantitative analysis of free enfortumab in human serum or plasma.
Qualitative ELISA for reactive or non-reactive assessment of anti-enfortumab antibodies using assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-ENF | ENF-FD-PAD | Quantitative | Free enfortumab | Human serum / plasma | 5 µL | 70 min | LOD 1.56 ng/mL; LOQ 2.7 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATENF | ENF-QLS-PAD | Qualitative | Anti-enfortumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Enfortumab Literature and Product-Use Records
Planning a Enfortumab research study?
Matrix Biotek can help identify the appropriate Enfortumab assay and prepare regional quotation and delivery information.